Based on a DCF model, Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) has an estimated fair value of $20.78, compared to a current price of $35.01.
Model Assumptions & Verdict
Using a WACC of 9.3%, a terminal growth rate of 2.5%, and projected FCF growth of 3.3%, the model suggests TEVA is currently overvalued with upside/downside of -40.6% versus the current price.
Verdict: Overvalued — Upside / Downside: -40.6%
DeepViews
VALUATION
DCF Valuation Calculator
DCF Calculator
This DCF calculator auto-populates financial data from SEC EDGAR XBRL filings. All assumptions are adjustable. Results update in real-time as you change inputs.
[01]
Enter Company Ticker
Quick search:
Model Inputs & Results
[02]DCF Assumptions
Growth Stage
Rate declines linearly to terminal rate over projection period
$0
Negative or zero FCF — DCF model is not applicable. Enter a positive value or use alternative valuation methods.
10.0%
-10%40%
Terminal Stage
Perpetuity growth after projection period
2.5%
0%5%
10.0%
4%20%
$0
0.00B
Search for a company to start DCF analysis
Enter a ticker symbol and data will auto-populate into the model
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.